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Abstract 
Purpose: To formulate matrix type sustained-release (SR) tablets of tizanidine hydrochloride (TH) for 
prolonged drug release and improvement in motor activity after spinal injuries. 
Methods: Matrix tablets were prepared by the wet granulation method using four polymers (hydroxyl 
propyl methyl cellulose [HPMC] K 100, ethyl cellulose [EC], guar gum, and polyvinylpyrrolidone (PVP 
K30) and characterized for hardness, friability, drug content, swelling, weight variation, in vitro drug 
release, and in vivo motor function activity using the spinal injury rat model.  
Results: All tablets showed good drug content, hardness, and other physicochemical properties. The 
tablet formulations showed a percent drug release ranging from 92.54 ± 1.02 to 98.56 ± 1.26 % at the 
end of 12 h. Using the spinal injury rat model, negative control had a motor activity of only 12.75 %, 
while F4 (containing HPMC, EC, and PVP) and F5 (containing EC, guar gum, and PVP) had motor 
activities of 62.25% and 57.5%, respectively, compared with 68.0 % for normal controls. 
Conclusion: SR matrix tablets of TH showed significant improvement in motor activity in post-traumatic 
spinal injury rat model.  
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Oral sustained-release (SR) drug delivery 
systems are designed to deliver therapeutically 
effective concentrations of drug to the systemic 
circulation over an extended period of time. In 
general, conventional dosage forms are 
associated with various limitations, such as drug 
plasma level fluctuations (leading to adverse 
effects or toxicity due to overdoses), high dosage 
frequency, high dosage requirements, and poor 
patient compliance. For effective treatment, the 
drug plasma concentration must be maintained 
within a therapeutic range. The SR form 
decreases side effects and increases patient 
compliance, due to reduction in frequency of 
dosing. The SR form also maintains constant 
blood levels, and avoids drug plasma level 
fluctuations associated with conventional 
immediate release formulations [1]. 
 
Spinal injury (SI), especially post-traumatic injury, 
can be devastating to the patient. To repair the 
initial tissue damage, SI leads to complex cellular 
and molecular interactions within the central 
nervous system, and is characterized by the 
shearing of cell membranes and axons, 
disruption of the blood-spinal cord barrier, cell 
death, immune cell transmigration, and myelin 
degradation [2-5]. 
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Neuropathic pain and inflammation greatly affect 
the quality of life after SI, and chronic pain is a 
very common and significant problem. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
and skeletal muscle relaxants are frequently 
used for alleviating the pain, inflammation, and 
spasticity [6,7]. The chronic pain associated with 
SI is effectively treated with muscle relaxants like 
tizanidine hydrochloride (TH).  
 
TH, an imidazole derivative, is an α-2-adrenergic 
receptor agonist which regulates myotonolytic 
effects of skeletal muscle. It reduces 
pathologically increased painful spasticity, 
especially in patients with spinal cord injury. In 
animal studies, its mechanism of action involves 
depressing polysynaptic reflexes, probably by 
antagonizing the excitatory actions of spinal 
interneurons [6-8]. In addition, it is effective in 
reducing muscle tone in spastic patients. TH is 
an antispastic agent with similar efficacy to that 
of baclofen, with a more favorable tolerability 
profile [9,10]. Furthermore, the benefits of 
administering TH in a modified release 
formulation have been demonstrated in clinical 
studies, with symptoms of spasticity and 
disability improved by approximately 94 % and 
79 %, respectively [10]. However, TH has a short 
half-life (2.5 h), and low bioavailability (40 %), so 
a frequent dosage regimen is required.  
 
Matrix tablets prepared with suitable polymers 
provide an effective approach in designing SR 
dosage forms [11-14]. Based upon these 
previous studies, a SR matrix tablet formulation 
of TH could result in a reduction in the 
administered dose and in its frequency of intake, 
and result in better patient compliance.  
 
In the present study, we formulated TH tablets 
using a wet granulation method, then 
characterized the SR matrix tablets using 
polymers [hydroxyl propyl methyl cellulose 
(HPMC), ethyl cellulose (EC), guar gum, and 
polyvinylpyrrolidone K-30 (PVP K-30)]. The 
resulting tablets were characterized for their in 
vivo motor function activity using the spinal injury 






TH, hydroxypropylmethyl cellulose (HPMC K 
100), EC, guar gum, PVP K-30, lactose, 
microcrystallin cellulose (MCC), and magnesium 
stearate were purchased from Sigma-Aldrich (St. 





Preparation of SR matrix tablets of TH 
 
TH matrix tablets were prepared by the wet 
granulation method (Table 1). 
 
For the preparation of tablets, all the powders 
were passed through 80 mesh (177 µm) filter. 
Drug and polymers (including granulating agents 
such as MCC and lactose) were mixed 
thoroughly in PVP solution (2 %), and then the 
resulting mass of cohesive material was passed 
through a 701 µm size mesh. The prepared 
granules were dried at 45 °C for 1 h, then talc 
and magnesium stearate were added. Finally, 
the tablets were compressed using a tablet 
compression machine (single punch tablet press; 




Tablet thickness were determined using a 
Vernier caliper, in three different positions for 
each tablet, followed by averaging the values (n 
= 6). Tablet hardness was measured using a 
Monsanto hardness tester (n = 6). 
 
A USP disintegration apparatus (BJ-1; Nade Lab 
Instrument Disintegration Testing Tablet 
Disintegration Tester, Zhejiang, China) was used  
 
Table 1: Composition of SR matrix tablets of tizanidine hydrochloride (per tablet) 
 





















F1 8 70 - - 15 25 35 3 3 
F2 8 - 70 - 15 25 35 3 3 
F3 8 - - 70 15 25 35 3 3 
F4 8 35 35 - 15 25 35 3 3 
F5 8 - 35 35 15 25 35 3 3 
F6 8 35 - 35 15 25 35 3 3 
Note: TH: Tizanidine hydrochloride; HPMC: hydroxyl propylmethyl cellulose; PVP K30: polyvinylpyrrolidone K30; 
MCC micro crystalline cellulose 
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to determine the disintegration time. A weight 
variation (WV) test was performed for 20 tablets 
from each batch, and the average values were 
calculated (Table 2). The percent weight 
variation was determined using equation 1:  
 
WV (%) = total weight of twenty tablets – sum of 
the individual weights of twenty tablets / total 
weight of twenty tablet × 100 ……………. (1) 
 
The friability test was performed using a Roche 
friabilator (CS2 Nade Lab Instrument 
Disintegration Testing Tablet Friability Tester, 
Zhejiang, China). Ten tablets were weighed and 
placed in the friabilator, rotating at 25 rpm. After 
100 revolutions, the tablets were dusted and 
reweighed. The percentage friability was 
determined using equation 2:  
 
Friability (%) = [(Wo – Wt) / Wo) × 100] …… (2) 
 
where Wo and Wt were the initial and final 





Ten tablets of each formulation were weighed 
and powdered. The quantity of powder 
equivalent to 100 mg of TH was placed in a 100 
mL volumetric flask and made up to the volume 
with phosphate buffer, pH 6.8. The contents were 
agitated on a magnetic stirrer at 37 °C for 24 h. 
At the end of 24 h, the contents were analyzed 
spectrophotometrically at 320 nm after suitable 
dilutions (Table 2). 
 
Swelling index  
 
Swelling studies were performed to assess the 
extent of swelling for different formulations. The 
percent swelling was determined using equation 
3:  
 
S (%) = [(Ws – Wd)/Wd] × 100 ………… (3) 
 
where Ws and Wd were the dry and swollen 
weights, respectively, at immersion time t in the 
test liquid. 
 
In vitro release studies 
 
In vitro dissolution studies of prepared tablets 
were performed in triplicate in a USP XXIII 8 
station dissolution test apparatus (ZRS-8L; 
Intelligent Dissolution Tester, Tianjin University 
Radio Factory, Tianjin, China) at 100 rpm and 37 
± 1 °C. Simulated gastric fluid (900 mL, without 
enzymes) was used as the media, and the study 
was performed for 12 h. In the first 2 h, 0.1 N HCl 
was used, which was changed to phosphate 
buffer pH 6.8 after 2 h. The medium was 
changed by vacuum filtration, and the 
undissolved particles were washed with pH 6.8 
phosphate buffer, then added again to the 
apparatus for further study. Aliquots of 5 mL 
were withdrawn at predetermined times and 
replaced with an equivalent amount of fresh 
dissolution media that was maintained at the 
same temperature. The withdrawn samples were 
filtered, diluted, and then recorded at 320 nm 
with a spectrophotometer. 
  
In vivo motor function activity of the spinal 
injury rat model 
 
Healthy male Wistar rats (200–250 g) were used 
for the study. The rats were kept in cages with 
standard environmental conditions of light and 
temperature. The rats were provided food and 
water ad libitum. Protocols of the animal studies 
were approved by the local Institutional Animal 
Care and Use Committee and performed in 
compliance with Directive 2010/63/EU on the 
handling of animals used for scientific purposes. 
Rats were divided into four groups (normal 
control, negative control, standard, and test 
groups) with six rats in each group. After 
administration of thiopental sodium (40 mg/kg), 
all animals were subjected to laminectomy 
(except the normal control group) to produce 
acute spinal injury by using an extradural 40 g 
force clip compression for 10 s at the T7 
vertebrae, until the motor nerve activity was most 
affected. One group of normal control animals 
did not undergo the laminectomy. After 10 h, the 
experiment was initiated. Control groups were 
fed a suspension of 2 % Tween 80. The standard 
group received methyl prednisolone (MP) (30 
mg/kg) intravenously at 30 min post injury. The 
test groups received an aqueous suspension of 
the TH SR tablets F4 and F5 per oral (p.o.) 
(1,000 µg/kg). At the end of 24 h, the motor 
nerve activity was determined by observing the 
performance of rats in the horizontal bar test. In 
this test, the rats were mounted on an assembly 
of a horizontal bar (2 mm diameter; 40 cm long) 
mounted on two supports, 50 cm in height. The 
rat was held by the tail, and allowed to touch the 
middle of the bar with only its forepaws. Its tail 
was released, and the stopwatch was 
simultaneously started. The time spent by rats on 
the horizontal bar was recorded, and scored as 
1–5 seconds = 1; 6–10 seconds = 2; 11–20 
seconds = 3; 21–30 seconds = 4; > 30 seconds = 
5; and touching of the bar support with a forepaw 
= 5. If 5 points were achieved, then a 4 mm 
diameter bar was used again for the same rat, 
with the addition of 2 in scoring for the respective 
timings. 
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Results were expressed as mean values and 
standard deviations (± SD), and the significance 
of the difference was analyzed by the Student’s t-
test, using Origin® 9 software, LA, US. A P-value 





The prepared SR matrix tablets of TH were 
evaluated for various physicochemical 
parameters (Table 2). 
 
The weight variations of all the formulations were 
not significant and were within the 
pharmacopoeia limits of ± 7.5%. The tablets also 
showed hardness in the range of 3.5 ± 0.75 
kg/cm2 to 5.5 ± 0.88 kg/cm2. The percentage 
friability was less than 1 % for all the 
formulations, indicating mechanical stability of 
the formulated tablets. Content uniformity for all 
formulations ranged from 94.72 ± 0.05 % to 
98.80 ± 0.03 %, and the contents were in 
compliance with pharmacopoeia limits. The 
highest swelling was found for formulation F6, 
which contained HPMC and guar gum.  
 
The percent cumulative drug release for all the 
formulations were in the following order: F5 > F4 
> F1 > F6 > F2 > F3 (Fig 1). 
 
Formulation F5 showed the higher drug content 
and highest cumulative drug release percentage. 
The best fit models for TH were the Higuchi 
models for F3 and F5, while the other models 
showed first-order release kinetics. The n values 
were greater than 0.6, suggesting non-Fickian 
diffusion (Table 3). 
 










uniformity*   
(%) 
    % 
Swelling* 
(4 hours) 
F1 150 ± 0.35 5.0 ± 0.59 0.42 ± 0.6 95.40 ± 0.05 39.4±0.101 
F2 150 ± 0.76 5.5 ± 0.88 0.45 ± 0.09 98.80 ± 0.03 34.7±0.009 
F3 150 ± 0.48 3.5 ± 0.75 0.72 ± 0.07 97.71 ± 0.02 42.2±0.023 
F4 149 ± 0.33 5.5 ± 0.38 0.21 ± 0.02 94.72 ± 0.05 24.0±0.103 
F5 150 ± 0.69 4.5 ± 0.75 0.68 ± 0.04 89.11 ± 0.01 49.0±0.03 
F6 149 ± 0.93 4.0 ± 0.23 0.77 ± 0.03 92.24 ± 0.20 52.02±0.02 
       *Mean ± standard deviation; F: formulation 
  
 
                Fig. 1: In vitro drug release of SR matrix tablet formulations of tizanidine hydrochloride 
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release Best fit model  
r2 r2 r2 r2 (n value) 
F1 0.565 0.819 0.796 0.776 (0.631) First order  
F2 0.740 0.921 0.918 0.825 (0.631) First order  
F3 0.786 0.923 0.940 0.839 (0.618) Higuchi  
F4 0.756 0.924 0.921 0.822 (0.620) First order  
F5 0.752 0.920 0.921 0.822 (0.620) Higuchi  
F6 0.772 0.948 0.930 0.825 (0.634) First order  
F: formulation; r2: regression coefficient 
 
Table 4: In vivo motor function activity of SR matrix 
tablets of tizanidine hydrochloride in the spinal injury 
rat model 
 
Group Total activity  
score* 
Control (normal) 8.70 ± 1.50 
Control (negative) 1.02 ± 1.20 
Standard (MP given i.v.) 5.44 ± 0.50 
Test (F4) 4.98 ± 0.10a 
Test (F5) 4.60 ± 0.24a 
*Experimental section describes the scoring system; ap 
< 0.05 was considered significant; i.v. = intravenous; F 
= formulation; MP = methyl prednisolone 
 
On the basis of the in vitro drug release results, 
tablet formulation F4 (containing HPMC and EC) 
and F5 (containing EC and guar gum) were 
selected for in vivo studies to assess the 
effectiveness of treating motor nerve activity in 
the post-traumatic spinal injury rat model. The 
results showed that the F4 formulation showed 
the best recovery from spinal injury, with F4 
(containing HPMC, EC, and PVP) and F5 
(containing EC, guar gum, and PVP) showing 
activity scores of 4.98 ± 0.10 and 4.60 ± 0.24, 
respectively, compared to a score of 5.44 ± 0.50 




TH, which is an imidazoline that acts as an 
agonist at α-2-adrenergic receptors, has been 
shown to be effective in reducing spasticity, and 
is an effective drug for spasticity induced by 
spinal injuries. Because of its swelling properties, 
previous studies reported that the matrix tablet 
showed prolonged durations of action [11-14], 
consistent with the observation that swelling is 
one of the most critical factors in sustaining drug 
release. In the present study, hydrophilic 
polymers like HPMC with guar gum (F6) showed 
good swelling, due to better imbibition of water or 
simulated gastric fluid. 
 
Swelling increased with time, and weight gain by 
prepared tablets increased in direct proportion 
with the rate of hydration, for up to 4 h. Later, it 
gradually decreased due to dissolution of the 
outermost tablet gel layer into the dissolution 
medium. In addition, the swelling was directly 
proportional to the polymer concentration. A 
matrix, upon contact with an aqueous solution, 
undergoes wetting, which starts from the surface, 
followed by the progression via microscopic 
pores into the inner core. The nature of the 
polymer therefore plays an important role in this 
swelling process. The presence of water in the 
polymer causes a stress, resulting in hydration of 
the polymer, which swells to yield a gelatinous 
viscous layer [15,16].  
 
When significant swelling occurs, the diffusional 
path length is increased, and drug release is 
retarded or sustained. The results of drug 
release in the present study were consistent with 
previous studies, which also reported that the 
amount of drug release was inversely 
proportional to the polymer concentration in 
prepared matrix tablets [11-12,17-22].  
 
The use of HPMC, EC, guar gum, and PVP in 
the polymeric granules not only provided 
sustained release, but also provided complete 
release from the SR tablets. Furthermore, the 
combination of HPMC and EC with PVP (F4) and 
EC and guar gum with PVP (F5) showed good in 
vitro, as well as in vivo, properties.  
 
After treatment, the negative controls had a 
motor activity of only 12.75 %, while the F4- and 
F5-treated animals had motor activities of 62.25 
and 57.5 %, respectively, compared with a motor 
activity of 68 % for the standard group. The 
increased motor activity was an indication of 
reduced spasticity. The rat model of spinal injury 
demonstrated the efficacy of TH SR tablets, as 
compared to that of the standard. The prolonged 
and sustained release profile may therefore be 
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suitable for patients with traumatic spinal injuries, 




Sustained release matrix tablets of TH prolong 
the time of drug release, and thus might be 
helpful in improving patient compliance and 
motor function activity in patients with post-
traumatic spinal injuries. The prepared 
formulations showed remarkable improvement in 
motor function activity in the traumatic spinal 
injury rat model. The formulations should 
therefore be further tested in patients with spinal 
injuries, to assess their possible neuroprotective 
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